Endologix to Present at the 25th Annual ROTH Conference
IRVINE, Calif., March 11, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc.
(Nasdaq:ELGX), developer and marketer of innovative treatments for aortic
disorders, announced today that John McDermott, President and Chief Executive
Officer and Shelley Thunen, Chief Financial Officer, are scheduled to present
at the 25th Annual ROTH Conference in Laguna Niguel, CA.
Event: 25th Annual ROTH Conference
Date: Monday, March 18, 2013
Time: 10:30 a.m. PT / 1:30 p.m. ET
An audio webcast of the Company's presentation will be available by visiting
the investor relations section of Endologix's website at www.endologix.com. A
replay of the presentation will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for
aortic disorders. Endologix focus is endovascular stent grafts for the
treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall
of the aorta, the largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if left
untreated, becomes increasingly susceptible to rupture. The overall patient
mortality rate for ruptured AAA is approximately 75%, making it a leading
cause of death in the U.S. Additional information can be found on Endologix's
website at www.endologix.com.
CONTACT: COMPANY CONTACT:
John McDermott, CEO
Shelley Thunen, CFO
The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020
Press spacebar to pause and continue. Press esc to stop.